Pune, India, January, 2017 /MRFR Press Release/- Market Research Future published a half cooked research report on global uterine sarcoma market.
Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth market growth. Moreover, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth during the forecast period. However, high cost of treatment and related side effects are the factors that can restrain the market growth.
The global uterine sarcoma market is expected to grow at an approximate CAGR of 8.5% during the forecast period.
The global uterine sarcoma market is segmented on the basis type, diagnosis, treatment, and end user.
On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.
On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. On the basis of end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others.
America dominates the global uterine sarcoma market. Increasing adoption of new technologies and huge patient population along with the rising healthcare expenditure and presence of a developed healthcare sector within the region are the drivers for the market growth.
Europe is second largest market share, in the global uterine sarcoma market owing rising research and development in healthcare sector and huge patient population. Presence of the developed economies like France, Germany, and Italy within the region facilitates the market growth during the forecast period.
Asia Pacific region is the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth.
The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of the Middle & Africa region is held by the Middle East.
Pfizer Inc. (U.S.), Intas Pharmaceuticals Ltd. (India), FMC Corporation (U.S.), Sun Pharmaceutical Industries Ltd. (India), Johnson & Johnson Services, Inc. (U.S.), General Electric Company (U.S.), Koninklijke Philips N.V. (the Netherlands), Siemens Healthcare Private Limited (Germany), and others.
Browse Full Report @ https://www.marketresearchfuture.com/reports/uterine-sarcoma-market-5131 .